{
    "paper_id": "PMC7177020",
    "metadata": {
        "title": "Discovery and Preclinical Work",
        "authors": [
            {
                "first": "Daria",
                "middle": [],
                "last": "Mochly-Rosen",
                "suffix": "",
                "email": "mochly@stanford.edu",
                "affiliation": {}
            },
            {
                "first": "Kevin",
                "middle": [],
                "last": "Grimes",
                "suffix": "",
                "email": "kgrimes@stanford.edu",
                "affiliation": {}
            },
            {
                "first": "Daria",
                "middle": [],
                "last": "Mochly-Rosen",
                "suffix": "",
                "email": "sparkmed@stanford.edu",
                "affiliation": {}
            },
            {
                "first": "Kevin",
                "middle": [],
                "last": "Grimes",
                "suffix": "",
                "email": "kgrimes@stanford.edu",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "In any drug discovery and development effort, we must accomplish a number of critical steps to arrive at a compound that is safe and efficacious, and also exhibits the complex array of desired drug-like behaviors that warrants advancement to the clinic. These tasks include target identification and validation; screening for active compounds; chemical modification of candidate compounds to achieve optimized pharmacology; formulating the final drug product; and establishing safety in preclinical models. \u201cRepurposing\u201d drugs that have previously been approved (or shown to be safe in humans) for new clinical indications can provide a faster, less risky, and more cost-effective route for bringing a new therapy to patients. Such shortcuts in development can be particularly valuable to resource-constrained academicians. When performing drug discovery research, we must be particularly attentive to the robustness of our experiments, because inability to reproduce academic data continues to be a sticking point when projects are transferred to industry. Our experiments must be appropriately blinded, statistically powered, and meticulously documented so that our findings are worthy of the large investment required for their further translation into a drug. This chapter walks through the essential preclinical drug development steps that lead to a clinical drug candidate.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 2.1: \nIn vitro test systems for intrinsic clearance\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Fig. 2.1: General high-throughput screen workflow",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Fig. 2.2: Plasma concentration curve with PK metrics",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Raising standards for preclinical cancer research",
            "authors": [
                {
                    "first": "CG",
                    "middle": [],
                    "last": "Begley",
                    "suffix": ""
                },
                {
                    "first": "LM",
                    "middle": [],
                    "last": "Ellis",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Nature",
            "volume": "483",
            "issn": "",
            "pages": "531-533",
            "other_ids": {
                "DOI": [
                    "10.1038/483531a"
                ]
            }
        },
        "BIBREF1": {
            "title": "A simple statistical parameter for use in evaluation and validation of high throughput screening assays",
            "authors": [
                {
                    "first": "JH",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "TDY",
                    "middle": [],
                    "last": "Chung",
                    "suffix": ""
                },
                {
                    "first": "KR",
                    "middle": [],
                    "last": "Oldenburg",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Biomol Screen",
            "volume": "4",
            "issn": "",
            "pages": "67-73",
            "other_ids": {
                "DOI": [
                    "10.1177/108705719900400206"
                ]
            }
        },
        "BIBREF2": {
            "title": "Mechanistic considerations in high-throughput screening",
            "authors": [
                {
                    "first": "RA",
                    "middle": [],
                    "last": "Copeland",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Anal Biochem",
            "volume": "320",
            "issn": "",
            "pages": "1-12",
            "other_ids": {
                "DOI": [
                    "10.1016/S0003-2697(03)00346-4"
                ]
            }
        },
        "BIBREF3": {
            "title": "Determining appropriate substrate conversion for enzymatic assays in high-throughput screening",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                },
                {
                    "first": "CN",
                    "middle": [],
                    "last": "Hodge",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J Biomol Screen",
            "volume": "8",
            "issn": "6",
            "pages": "694-700",
            "other_ids": {
                "DOI": [
                    "10.1177/1087057103260050"
                ]
            }
        },
        "BIBREF4": {
            "title": "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings",
            "authors": [
                {
                    "first": "CA",
                    "middle": [],
                    "last": "Lipinski",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Lombardo",
                    "suffix": ""
                },
                {
                    "first": "BW",
                    "middle": [],
                    "last": "Dominy",
                    "suffix": ""
                },
                {
                    "first": "PJ",
                    "middle": [],
                    "last": "Feeney",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Adv Drug Delivery Rev",
            "volume": "23",
            "issn": "",
            "pages": "3-25",
            "other_ids": {
                "DOI": [
                    "10.1016/S0169-409X(96)00423-1"
                ]
            }
        },
        "BIBREF5": {
            "title": "",
            "authors": [
                {
                    "first": "RM",
                    "middle": [],
                    "last": "Rydzewski",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Real world drug discovery: a chemist\u2019s guide to biotech and pharmaceutical research",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Structural basis for ligand promiscuity in cytochrome P450 3A4",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ekroos",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Sjogren",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "PNAS",
            "volume": "103",
            "issn": "",
            "pages": "13682-13687",
            "other_ids": {
                "DOI": [
                    "10.1073/pnas.0603236103"
                ]
            }
        },
        "BIBREF7": {
            "title": "Believe it or not: how much can we rely on published data on potential drug target?",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Prinz",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Schlange",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Asadullah",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Nat Rev Drug Discov",
            "volume": "10",
            "issn": "",
            "pages": "328-329",
            "other_ids": {
                "DOI": [
                    "10.1038/nrd3439-c1"
                ]
            }
        },
        "BIBREF8": {
            "title": "The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "King",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Sarvetnick",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "PLoS ONE",
            "volume": "6",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1371/journal.pone.0017049"
                ]
            }
        },
        "BIBREF9": {
            "title": "Six red flags for suspect work",
            "authors": [
                {
                    "first": "CG",
                    "middle": [],
                    "last": "Begley",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nature",
            "volume": "497",
            "issn": "",
            "pages": "433-434",
            "other_ids": {
                "DOI": [
                    "10.1038/497433a"
                ]
            }
        },
        "BIBREF10": {
            "title": "In search of preclinical robustness",
            "authors": [
                {
                    "first": "IS",
                    "middle": [],
                    "last": "Peers",
                    "suffix": ""
                },
                {
                    "first": "PR",
                    "middle": [],
                    "last": "Ceuppens",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Harborn",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Nat Rev Drug Discov",
            "volume": "11",
            "issn": "",
            "pages": "733-734",
            "other_ids": {
                "DOI": [
                    "10.1038/nrd3849"
                ]
            }
        },
        "BIBREF11": {
            "title": "The importance of new companies for drug discovery: origins of a decade of new drugs",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Kneller",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Nat Rev Drug Discov",
            "volume": "9",
            "issn": "",
            "pages": "867-882",
            "other_ids": {
                "DOI": [
                    "10.1038/nrd3251"
                ]
            }
        },
        "BIBREF12": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Southall",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Sci Transl Med",
            "volume": "3",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1126/scitranslmed.3001862"
                ]
            }
        },
        "BIBREF14": {
            "title": "Reengineering translational science: the time is right",
            "authors": [
                {
                    "first": "FS",
                    "middle": [],
                    "last": "Collins",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Sci Transl Med",
            "volume": "3",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1126/scitranslmed.3002747"
                ]
            }
        }
    }
}